Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the topical use of systemic drugs for cutaneous disorders and reports a lack of strong evidence from randomized controlled trials, highlighting the need for larger comparative effectiveness studies.

In this observational study conducted in Bengaluru, India, among 272 dermatology patients, the authors reported that dermatitis was the most common condition treated with corticosteroids, with a preference for topical applications; desonide was the most frequently prescribed drug.

This review discusses the disparities in approved treatments and evidence-based guidelines for various chronic skin diseases, highlighting greater unmet medical needs in conditions like hidradenitis suppurativa, alopecia areata, and vitiligo compared to psoriasis and atopic dermatitis.

This case report describes a patient who developed drug-induced lupus erythematosus after treatment with a monoclonal antibody combination against the SARS-CoV-2 surface protein, highlighting the need for careful follow-up.

This study examined 27 DRESS patients diagnosed in Thailand, identifying phenytoin, allopurinol, and nevirapine as common causes, with a 3.7% mortality rate and systemic corticosteroids being a common treatment.

This study reports that various types of alopecia, including permanent alopecia, can persist after an acute DRESS episode, but telogen effluvium and alopecia areata showed clinical improvement with treatment within six months.

This article reviews how various chemical agents affect human hair and skin, suggesting the need for more research on their pharmacologic and dermatologic effects; it does not report new experimental results.

This review discusses drug-induced hypersensitivity syndrome and drug reaction with eosinophilia and systemic symptoms, highlighting clinical features, potential viral reactivations, and treatment, but reports no new clinical findings.

This study emphasizes the importance of regular dental check-ups for patients undergoing systemic treatments for psoriatic disease, as it helps prevent oral complications associated with these medications. It recommends collaboration between dermatologists and oral health specialists to effectively manage and communicate these risks.

Severe digestive issues in DRESS need early endoscopy for better treatment.

Baricitinib effectively regrew hair in a woman with alopecia universalis after other treatments failed.

This study reviewed data from three hospitals and found that alopecia after DRESS occurred more often in severe cases, but the rate of corticosteroid treatment did not significantly differ between patients with and without alopecia.

This chapter reviews common drug-related and systemic disorder-induced alopecias, focusing on their epidemiology, causes, symptoms, diagnosis, and treatment, but reports no new findings.

Viral reactivation is rare at the time of DRESS diagnosis in the U.S.

Sulfasalazine can cause severe allergic reactions leading to long-term autoimmune issues like hair loss and skin discoloration.

In this retrospective cohort study, researchers reported that 11.5% of patients with DRESS developed significant long-term autoimmune or renal sequelae, with age influencing the type of sequelae observed.

This study found that DEB-BACE combined with systemic chemotherapy was more effective than chemotherapy alone for unresectable lung squamous cell carcinoma, reducing side effects and improving survival rates.

This case study reports that a woman with systemic lupus erythematosus experienced remission of her symptoms after receiving a combined therapy of corticosteroids and cytostatics.

This case report describes a 6-year-old who developed autoimmune conditions including type III polyglandular autoimmune syndrome following drug-induced hypersensitivity syndrome, prompting an investigation into associated triggering factors.

This article highlights the importance of recognizing, preventing, and reporting adverse drug reactions to the FDA's MedWatch program, but it presents no new research findings.

This study describes a case where stopping infliximab and using oral minocycline with topical treatments effectively resolved alopecia and scalp psoriasis in a woman with Crohn's disease.

This review examines systemic drugs that can cause changes in hair color and emphasizes the importance of reporting these adverse events, but it does not include new clinical outcomes.

This article outlines manifestations of systemic lupus erythematosus, noting rapid joint symptom improvement with corticosteroids and antimalarial drug responsiveness for skin symptoms, and links anti-Ro with photosensitive rash and subacute lupus.

This study used data mining of the FDA Adverse Event Reporting System to analyze drug-induced pruritus, revealing differences in gender, age, and weight among cases, and identified ophthalmic drugs and systemic antibacterials as common triggers, contributing to potential prevention and treatment strategies for pruritus.

This review discusses various strategies to enhance drug delivery through the skin barrier, highlighting liposomes as promising carriers for increased dermal concentrations in topical therapies, but reports no new research results.

This review examines the role of hair follicles and sebaceous glands in percutaneous drug delivery but does not report new clinical results; it calls for further exploration of follicle-targeting therapies.

This retrospective study observed that while systemic lupus erythematosus patients at King Fahd Hospital in eastern Saudi Arabia had similar clinical manifestations to those in other regions, there were differences in age of onset and sex distribution.

This review explored the new and emerging treatments for androgenetic alopecia and alopecia areata, finding that JAK inhibitors show promise for alopecia areata, while advancements in stem-cell research may eventually lead to new and improved treatments for androgenetic alopecia.

This review discusses the potential of Janus Kinase inhibitors for treating alopecia areata and other forms of alopecia, highlighting the need for further research on their long-term safety and optimal formulation.